







































Prevalence of Antimicrobial-Resistant (R) Pathogens Causing Hospital-Onset Intensive Care Unit Infections: 5 years **Organism** %Increase* Fluoroquinolone-R Pseudomonas spp. 2657 49% 3rd generation cephalosporin-R E. coli 1551 48% Methicillin-R Staphylococcus aureus 2546 40% Vancomycin-R enterococci 4744 40% Imipenem-R Pseudomonas spp. 1839 20% * Percent increase in proportion of pathogens resistant to indicated antimicrobial Source: National Nosocomial Infections Surveillance (NNIS) System



Drug-resistant pathogens are a growing threat

- Each year ~2 million patients get an infection in US hospitals, about 90,000 of these die
- More than 70% of bacteria causing hospitalassociated infections are resistant to ≥1 drug most commonly used to treat them
- Persons infected with drug-resistant organisms are more likely to have longer hospital stays and require treatment with less effective, more toxic, and/or more expensive drugs

http://www.cdc.gov/drugresistance/healthcare/problem.htm

Resistance Expanding in the Community: S. aureus

- 25-30% of healthy people are colonized with Staphylococcus aureus
- Generally this poses little risk, considered 'normal flora'
- In past 5 years, there are increasing cases, outbreaks and deaths among healthy persons with a new community strain of antibiotic-resistant *S. aureus*

The Human Face of MRSA: Carlos

 1/07 Carlos Don, 12 years old, returned from a school trip with flulike symptoms. Started antibiotics, hospitalized on a ventilator, died



The Human Face of MRSA: Simon

 Healthy Simon, aged 14 months, mother with doctorate in public health, died within 24 hrs of MRSA sepsis



The Human Face of MRSA: Brandon

· Washington Redskins defensive tackle Brandon Noble after knee surgery. "This infection has had a huge impact on my life and will continue to impact me and my family in the near future. Hopefully, I am not a carrier and will not have to worry about this forever."





The Human Face of MRSA: Bryce

- A healthy 14month old who contracted MRSA and spent weeks ICU. Survived.
- · Medical bills to date: ~\$1 million



One Typical Day: 11/12/07

- Chicago Tribune: Superbugs Spur FDA, Drug Firms To Action Associated Press: Staph Germ Undermines Body's Defenses LA Times: "Superbug's Killer Cousin; An Antibiotic-Resistant Staph Strain TriCitles.com (TN):Staph Infections Aren't New The Courier News (IL):Staph Myth Debugged Wash Post: FDA Approves Products That Reduce Spread Of Dangerous Bacteria

- Bacteria Wash Post-Are Antimicrobial Soaps Breeding Tougher Bugs? Rochester Democrat and Chronicle (NY):MRSA Increase Is Warning To Use Antibiotics Wisely Business Wire: Tommy G. Thompson Speaks Out Against Misinformation Regarding MRSA "Superbug"
- The Columbus Dispatch (OH):Deadly Threat; Infections Are Reminder That Antibiotics Need Protection Antuioottcs Need Protection Chicago Tribune:Garlic vs. Superbug' Akron Beacon Journal (OH): Officials Seek To End Staph Misinformation Associated Press: Gregoire Asks Dept Of Health To Convene MRSA Panel US Fed News: Sen. Brown Introduces Strategies To Address Antimicrobial Resistance Act

- Resistance Act States News Service: With Lethal MRSA Infection Continuing To Pop Up In Schools Across NYS, Schumer Bill Will Provide Tax Credit For Research And Development Of Products To Combat Infectious Diseases Tallahassee Democrat (FL): Know The Facts About MRSA Infections









- Rationale is to promote more rapid growth reducing farming expenses
- Mechanisms are debated although most commonly invoked is the reduction of infections, especially in unsanitary conditions
- Many of the antibiotics used in this setting are of the same class as those used to treat human infections

 Macrolides, tetracyclines, glycopeptides





Chronology/History: 1940s-50s

- 1940: Pathologist Florey discovers killing properties of penicillin, which was first widely available antibiotic and used in WWII for soldiers
- 1943: Drug companies mass produced
- 1958: Nobel Prize for discovery of bacteria's ability to exchange genetic material

Chronology/History: 1960s

- Fast-developing resistance, but large number of new antibiotics enter market
- 1960: Methicillin introduced
- 1961: MRSA turns up in UK hospital
- 1963: MRSA appears in Denmark
- 1967: Penicillin-resistant streptococcal pneumonia in New Guinea

Chronology/History: 1970s-80s

- Antibiotics routinely prescribed for viral infections (e.g. colds), strong antibiotics used for transplants, cancer
- 1977: Strep pneumonia bacterium resistant to every available drug (S.Afr)
- 1983: 18 people hospitalized for Ab-resistant salmonella from beef fed Abs
- 1986: Sweden bans Abs for animal food

Chronology/History: 1990s

- Drug firms reduce Ab R&D
- 1992: Ab-resistant infections kill 13,000 hospital patients
- 1998: Denmark taxes Abs used as animal growth promoters. EU bans use of human Abs for animals feed
- 1999: US Fed Interagency Task Force on AM Resistance launched

Chronology/History: 2000s

- 2000: Congressional Act to take strong steps to reduce resistance is not funded. Public health efforts lag
- 2001: Anthrax scare results in stockpiling cipro
- 2003: Drug resistant *Acinetobacter* infection Iraqi War soldiers, leading to many amputations



Chronology/History: 2000s

- 2005: France bans 12 sore-throat medications containing antibiotics
- 2006: EU bans using any antibiotic to promote animal growth
- US STILL has made minimal similar efforts

Chronology/History: 2007

- Cases of MDR-TB quadruple in S. Afr
- WHO launches plan to fight MDR-TB
- Avian flu virus is evolving to be resistant to current vaccine strains
- 10 times as many cases of MRSA in hospitals than previously thought
- FDA still considering approval for a new Ab for cows that could increase resistance in Abs used in humans
- CQ Researcher 2007; 17:683

MDR-TB

- Kills ~2 million worldwide annually
- MDR-TB has doubled in past few years in many countries (WHO)
- Summer 2007: Andrew Speaker: Healthy US newlywed on honeymoon had MDR-TB. Where did he get it?
- Only 30-50% of those with extensively resistant strains recover





Attributable Costs of Resistance

MRSA (vs MSSA)

- Bacteremia¹
 - Median hospital stay increased by 2 days
 Median hospital charges increased \$6916
 - Median hospital charges increa
- Surgical site infection²
 - Median hospital stay increased by 5 days
 - Median hospital charges increased \$13,901

FOR MORE INFO...

1. Cosgrove SE et al. Infect Control Hosp Epidemiol 2003 2. Engemann JJ et al. Clin Infect Dis 2003

> MRSA Prevalence Survey: NYS Prisons

	Sing Sing	Bedford Hills
Number of inmates	1741	792
Ethnic status (%)		
African American	55	50
Hispanic	31	22
White	11	27
Average length of incarceration (months)	21	38
No prior arrest	17	37
No prior conviction	6.5	7.5
Prior jail term	17.5	21
Violent felony	80	65
Drug felony	12	10



Results: Feb-May 2006				
• S. aureus positive	• 25.5 (124/487)			
• MRSA	• 10.5 (13/124)			
SCCmec type IV	• 100 (13/13)			
• PVL + MSSA	• 21.6 (24/111)			
• PVL + MRSA	• 61.5 (8/13)			

Staphylococcus aureus Reports Lab A: April – October 2005 Manhattan

• MSSA	58%	(446)
• MRSA	35%	(270)





_			
_			











-			





Summary: CA-MRSA cases differ significantly from NYC population

- Predominantly male
- White, non-Hispanic
- Higher proportion 24-64 y-o
- Affluent
- Highly educated
- Concentrated in Manhattan

"At the beginning of the 21st century, antimicrobial resistance is common, has developed against every class of antimicrobial drug, and appears to be spreading into new niches."

http://www.cdc.gov/ncidod/EID/vol11no06/05-0167.htm













Antibiotic Resistance Genes in Multidrug-Resistant Acinetobacter sp. Isolates from Patients Treated at the Walter Reed

Sixteen unique resistance genes and four mobile genetic elements detected in 75 unique patient isolates

- 89% resistant to at least 3 antibiotic classes; 15% resistant to all antibiotics tested
- Eight major clonal types, very complex genetic background

Hujer et al, Antimicrob Agents Chemother 2006; 50:4114-23.







Mechanisms of Resistance

- Emergence, which occurs because of microbial evolution
- Dissemination of resistant organisms
 - at the microbial level (e.g. clonal spread, plasmids, transposons)
 - at the population level (e.g. hospital or community spread)

Courvalin P. Emerg Infec Dis http://www.cdc.gov/ncidod/EID/vol11no10/05-1014.htm

Characteristics that Enhance Resistance

- Speed. Bacterial populations can double ~ every 20 mins
- Exchangeability. Bacteria can exchange genetic material
- Mutation. Under antibiotic pressure, resistant mutants emerge



Capsules

Three Fundamental Mechanisms

- Enzymatic degradation of antibacterial drugs
- Alteration of bacterial proteins that are antimicrobial targets, and
- Changes in membrane permeability to antibiotics.



















Discussion

- Determine at least 2-3 actions that could be taken to reduce resistance by

 The public
 - The healthcare community
 - The government
- Develop a plan of action for making this happen
- Describe how you would evaluate the effectiveness of this plan

Avoiding Resistance: What the Public Can Do

- Careful hygiene, particularly in moist, busy environments such as gyms
- Don't share towels, clothes
- Avoid antibacterial soaps with triclosan; consider using alcohol rubs
- Don't demand Abs for viral infections
- Don't save or take anybody else's Abs
- Find out about hospital infection rates

Public Knowledge/Attitudes

- 453 Wash Heights households interviewed (2,386 people)
- 88% thought colds were caused by bacteria
- Only 29.8% agreed that most colds and flu would improve without medication
- 89.9% stated that antibiotics are usually or sometimes needed to treat viral throat infections
- 27.6% stated that Abs were usually or sometimes indicated for asthma attacks.

Antibiotics without Prescription

- Availability of antibiotics without prescription in New York City
- 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, 10/04.



Larson & Figueroa, J Urban Health 2004; 81:498-504

Methods

Survey of all independent pharmacies, grocery stores, delicatessens, bodegas and botanical or health food stores in 30 blocks of the major commercial areas of three neighborhoods were surveyed:

Predominantly Hispanic neighborhood (Washington Heights) Predominantly Black neighborhood (Central Harlem) Predominantly Caucasian neighborhood (Upper West Side)

Procedure

 A trained surveyor of same ethnicity as the neighborhood residents entered each store and ascertained whether antibiotics were available on the shelf or upon request to the store attendant.





Results

- 101 stores were surveyed
- No antibiotics were available in the predominantly Black or Caucasian neighborhoods
- In 7/34 (20.6%) of stores in the Hispanic neighborhood, antibiotics were available on the shelves, and were also available upon request in all other stores



What Types?

- Antibiotics offered included ampicillin, amoxicillin, tetracycline, erythromycin
- Antibiotics were offered as single doses individually wrapped and in larger quantities.





Clinician Prescribing Patterns: Community

- Rates of prescribing antibiotics for viral URI range from 25-56%
- When presented with clinical scenarios of viral pharyngitis, 81% of 948 clinician respondents used an inappropriate treatment strategy
- 22% of 1,363 ED visitors reported that their physician routinely prescribed Abs for a cold
- >800 physicians rated the issue of resistance as the lowest of seven determinants of their choice regarding antibiotic prescribing

Nurse Practitioners (NP)

- Survey of 149 (48%) educational programs
- 45.3% reported <4 hours of lecture on antimicrobial therapy, but 51.9% did not offer a microbiology course (sym, et.al. J Am Acad Nurse Pract 2007, 19:477-485).
- National NP guidelines do not include competencies regarding antimicrobial resistance and/or proper antibiotic prescribing
- NPs misuse and overuse antimicrobial agents in a similar fashion to physicians.

Avoiding Resistance: What Healthcare Systems Can Do

- Control antibiotic use
- Prevent cross-transmission between patients and from healthcare worker to patient
 - Appropriate barrier techniques (cohorting, isolation)
 - Appropriate hygiene, particularly hands
- Identify and act on infections rapidly





Current Status in Hospitals • 34/1000 patients have active HA-MRSA infections and 12/1000 additional are colonized • About 1.2 million patients infected annually • Resistance increasing similarly in other organisms

- 59.8% of patients received one of 50 antibacterial agents (1,074,174/1,795,504)
- 776/1000 patient days
- 792 doses/100 patient days

Polk et al. CID 2007; 44:664-70







Potential Barriers to Adherence to Guidelines

Knowledge

Lack of awareness – No knowledge of CDC 12 Steps

Lack of familiarity – Unfamiliar with 12 Steps in general or with specific component(s)

Potential Barriers to Adherence to Guidelines

Attitude

Lack of agreement – Disagreement with CDC 12 steps or with specific component(s)

Lack of self efficacy - Perceived lack of confidence or lack of preparation to perform specific guideline(s)

Lack of outcome expectancy – Lack of belief that guideline(s) will lead to an important patient outcome

Potential Barriers to Adherence to Guidelines Practice

Frequency (Adherence) - How often guideline(s) are followed

External factors - Lack of time, support staff, administrative support, and/or financial reimbursement

Cabana MD, et al. Why Don't Physicians Follow Clinical Practice Guidelines? A Framework for improvement. JAMA 1999; 282:1458-1465

Survey

 Neonatology fellows and faculty attending a conference *"Infection and Immunity in the Preterm Infant"* at the 70th Annual Perinatal Development Symposium on June 1, 2007

 Used with permission from Patel S, Saiman L. Columbia University Department of Pediatrics.

Knowledge Lack of Awareness

- Awareness of 12 Step Campaign
 - 59% not aware of the campaign
 - 25% somewhat aware
 - 16% very aware
 - 28% received educational materials
 (including 4 unaware of 12 Steps)

Outbreak of Multidrug-Resistant Acinetobacter in the US Military Health Care System Associated with Military Operations in Iraq

- Evaluated 3 potential sources: patient skin, soil, healthcare environment
- Prevalence
 - Skin: 1/160 patients (0.6%)
 - Soil: 1/49 samples (2%)
 - Environment: 7/7 hospitals (100%)
- Environmental contamination played a major role

Scott et al, Clin Infect Dis 2007; 44:1577-84









Avoiding Resistance: What Can Government Do?

- · Good surveillance: National Antibiotic **Resistance Monitoring System (NARMS) is** run on a shoestring
- · Stricter tabs and regulations regarding Ab use in humans and animals
- · Private sector has been unwilling on its own
- · Better support of development of new Abs
- · Funds for social marketing campaigns

IDSA recommendations

- · "Wild-card patent extension."
- A company could extension." A company could extend the market exclusivity period of another FDA-approved drug as long as the company commits to invest a portion of the profits derived during the extension period back into antibiotic R&D.
- Restoration of all patent time lost during FDA's review of priority antibiotics Extended market exclusivity similar to what has been
- successfully implemented for pediatric and orphan drugs Other potential statutory incentives:
- Tax incentives for R&D of priority antibiotics Measured liability protections
- Additional statutory flexibility at FDA regarding approval of antibiotics, as needed
- Antitrust exemptions for certain company communications
- A guaranteed market

http://www.idsociety.org/temp.aspx?RefURL=http%3a%2f%2fold.idsociety.org%3a80%2fTemplate.cfm%3fSection%3dAntimicrobials%26Template%3d%2fContentManagement%2fContentDisplay.cfm%26ContentID%3d9770



STARR Act



Will It Work?

- In European countries (e.g. Netherlands, Denmark) where hospital stringent policies regarding are in place, rates of MDRO have dropped precipitously
- No mechanism in US to mandate such policies; must be done on an individual system or institution basis.

TELECLASS EDUCATIO	2008
A	Full Year Subscription Save More Than 50%
WWW.We	ebbertraining.com/subscriptioninfoc50.php
	"No Barriers"

Thanks to

• M. Blaser, F. Lowy, R. Weinstein, M. Marx, A. Ratner, S. Patel from whom slides were obtained with permission